Dr. Lal PathLabs Limited
1,844.30
INR
+9.40
(+0.51%)
ISIN
INE600L01024
Return %
Stock
S&P 500
1Y
17.52
14.20
3Y
47.24
81.12
5Y
8.87
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Shankha Banerjee
- Full Time Employees
- 6,200
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Tower B, SAS Tower Gurgaon HA India 122001
- IPO Date
- Dec 23, 2015
- Website
- lalpathlabs.com
- Similar Companies
- Business
- Dr. Lal PathLabs Limited is a leading Indian provider of diagnostic and healthcare testing services. The company operates an extensive network of over 200 laboratories and more than 5,000 specimen collection centers across India, servicing a broad spectrum of pathology, radiology, cardiology, and molecular diagnostics tests. Its core product offerings include blood and urine tests, genomic profiling, myeloid testing for hematological malignancies, autoimmune disorder diagnostics, amyloid typing solutions, comprehensive health screening packages such as SwasthFit, and advanced diagnostics powered by technologies like next-generation sequencing and artificial intelligence. Founded in 1949 and headquartered in Gurugram, India, Dr. Lal PathLabs serves patients and healthcare providers both domestically and internationally. The company focuses on delivering high-quality, accessible diagnostic services across metropolitan, tier 1, and expanding tier 3 and tier 4 cities. It operates specialized divisions like Genevolve for genomics. It has partnerships with prominent technology firms such as Illumina to enhance its genomic testing capabilities, exemplified by the recent integration of Illumina’s NovaSeq X Series, advancing its precision and research offerings. In recent developments, Dr. Lal PathLabs launched India's first dedicated Complement Testing Lab in November 2025 to support autoimmune and kidney disease diagnostics. It has also entered a strategic partnership with SAMRIDH Impact Solutions to bolster healthcare innovation and support early-stage diagnostic startups. The company is actively pursuing growth through geographic expansion, particularly targeting acquisitions to strengthen its presence in South India, a region historically underpenetrated by its services. It is considering acquisitions in the INR 3,000-4,000 crore range to consolidate its market leadership. Alongside expansion, it continues to invest in digital technologies, artificial intelligence, and laboratory information systems to improve operational efficiency and patient experience. Dr. Lal PathLabs holds key industry accreditations including ISO 9001 and NABL certification. It operates in the diagnostic and healthcare sectors with a focus on clinical laboratories, pathology, radiology, cardiology, and molecular diagnostics markets. The company has strengthened its product and service portfolio with advanced test launches, including specialized amyloid typing under expert international guidance and ongoing development of bundled health packages for underserved markets. Overall, Dr. Lal PathLabs Limited is a dominant diagnostics chain in India with substantial investments in technological advancement, strategic partnerships, and market expansion initiatives, underscoring its commitment to accessible and cutting-edge diagnostic healthcare solutions.